Name: NUREXONE BIOLOGIC INC (NRX) Stock
Brand: NUREXONE BIOLOGIC INC
Rating: 3 (3 reviews)

NRX.CA Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: NurExone Biologic Inc

NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises

14 days ago - By: NurExone Biologic Inc

NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing

a month ago - By: NurExone Biologic Inc

NurExone Invited Presenter at Precision EV Forum in Cambridge, UK

a month ago - By: NurExone Biologic Inc

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

2 months ago - By: NurExone Biologic Inc

NurExone Planning to Establish First U.S. Commercial Manufacturing Facility in Indiana

2 months ago - By: NurExone Biologic Inc

NurExone Biologic Announces Corporate Updates including Israel Patent Grant and Private Placement Closing

2 months ago - By: NurExone Biologic Inc

NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness

3 months ago - By: NurExone Biologic Inc

NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

3 months ago - By: NurExone Biologic Inc

NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment

3 months ago - By: NurExone Biologic Inc

NurExone’s Exosomes Show Stronger Healing Potential Than Industry Standard

4 months ago - By: NurExone Biologic Inc

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

4 months ago - By: NurExone Biologic Inc

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model

5 months ago - By: NurExone Biologic Inc

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

6 months ago - By: NurExone Biologic Inc

NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation

6 months ago - By: NurExone Biologic Inc

NurExone Announces Clinical Trial Plans for Acute Spinal Cord Injury Therapy at Annual Meeting of American Spinal Injury Association

6 months ago - By: NurExone Biologic Inc

NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: NurExone Biologic Inc

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025

7 months ago - By: NurExone Biologic Inc

NurExone Expands European Engagement with Investor Events in Germany and Switzerland

7 months ago - By: NurExone Biologic Inc

NurExone to Showcase Breakthrough in Facial Nerve Regeneration at ISEV 2025

7 months ago - By: NurExone Biologic Inc

NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario

7 months ago - By: NurExone Biologic Inc

NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: NurExone Biologic Inc

NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement

8 months ago - By: NurExone Biologic Inc

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery

9 months ago - By: NurExone Biologic Inc

NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award

9 months ago - By: NurExone Biologic Inc

NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock

9 months ago - By: NurExone Biologic Inc

NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation

10 months ago - By: NurExone Biologic Inc

NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization

10 months ago - By: NurExone Biologic Inc